早期减少Aβ可预防脑淀粉样血管病进展
该研究在APPDutch小鼠模型中,从CAA发病时开始使用BACE1抑制剂治疗4个月,使脑脊液中Aβ减少90%,并 largely 预防了CAA进展及相关病理。脑脊液Aβ40和Aβ42联合下降是血管淀粉样变的特异性生物标志物。
要点
- CAA发病时脑脊液Aβ40和Aβ42联合下降是血管淀粉样变的特异性标志。
- 从CAA发病开始使用BACE1抑制剂可使脑脊液Aβ减少90%。
- 早期减少Aβ可 largely 预防无实质淀粉样变的CAA进展。
核心结论
- 早期疾病时间点减少Aβ可在无实质淀粉样变的情况下 largely 预防CAA。
研究设计与样本
- 使用APPDutch小鼠(模拟遗传性荷兰型脑出血伴淀粉样变,无实质淀粉样变)进行BACE1抑制剂治疗研究。
主要发现
- 小鼠CAA发病在22至24月龄,首先累及额部软脑膜和浅层皮质血管,随后累及穿透皮质层的血管。
- 脑脊液Aβ随衰老增加,CAA发病时Aβ40和Aβ42均下降。
- 从CAA发病开始治疗4个月,脑脊液Aβ减少90%,并 largely 预防CAA进展及相关病理。
关键数值与推荐
- 脑脊液Aβ40和Aβ42联合下降是血管淀粉样变的特异性生物标志物。
临床怎么用
- 为CAA风险患者和症状前HCHWA-D患者的Aβ减少治疗提供临床前依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical trials targeting β-amyloid peptides (Aβ) for Alzheimer disease (AD) failed for arguable reasons that include selecting the wrong stages of AD pathophysiology or Aβ being the wrong target. Targeting Aβ to prevent cerebral amyloid angiopathy (CAA) has not been rigorously followed, although the causal role of Aβ for CAA and related hemorrhages is undisputed. CAA occurs with normal aging and to various degrees in AD, where its impact and treatment is confounded by the presence of parenchymal Aβ deposition. METHODS: APPDutch mice develop CAA in the absence of parenchymal amyloid, mimicking hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWA-D). Mice were treated with a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor. We used 3-dimensional ultramicroscopy and immunoassays for visualizing CAA and assessing Aβ in cerebrospinal fluid (CSF) and brain. RESULTS: CAA onset in mice was at 22 to 24 months, first in frontal leptomeningeal and superficial cortical vessels followed by vessels penetrating the cortical layers. CSF Aβ increased with aging followed by a decrease of both Aβ40 and Aβ42 upon CAA onset, supporting the idea that combined reduction of CSF Aβ40 and Aβ42 is a specific biomarker for vascular amyloid. BACE1 inhibitor treatment starting at CAA onset and continuing for 4 months revealed a 90% Aβ reduction in CSF and largely prevented CAA progression and associated pathologies. INTERPRETATION: This is the first study showing that Aβ reduction at early disease time points largely prevents CAA in the absence of parenchymal amyloid. Our observation provides a preclinical basis for Aβ-reducing treatments in patients at risk of CAA and in presymptomatic HCHWA-D. ANN NEUROL 2019;86:561-571.
引用
- Schelle J, Wegenast-Braun BM, Fritschi SK, et al. Early Aβ reduction prevents progression of cerebral amyloid angiopathy. Ann Neurol. 2019. PMID: 31359452. doi:10.1002/ana.25562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。